US Broker Ratings

Orthofix Medical Inc. (OFIX): Investor Outlook with a 50.40% Potential Upside

Orthofix Medical Inc. (NASDAQ: OFIX), a prominent player in the healthcare sector specializing in medical devices, presents a compelling investment opportunity. With a market capitalization of $600.33 million, the company’s..

Semler Scientific, Inc. (SMLR) Investor Outlook: A Potential 329% Upside in the Medical Device Sector

Semler Scientific, Inc. (NASDAQ: SMLR) presents a compelling opportunity for investors intrigued by the healthcare sector, specifically within the burgeoning field of medical devices. Headquartered in Santa Clara, California, this..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 14.81% Potential Upside in the Biotech Arena

For investors keen on the biotechnology sector, Keros Therapeutics, Inc. (NASDAQ: KROS) presents a compelling opportunity. With a market capitalization of $620.29 million, this clinical-stage biopharmaceutical company is focused on..

Intellia Therapeutics (NTLA) Investor Outlook: Analyzing the 149% Upside Potential

For investors keeping a close watch on innovative biotechnology firms, Intellia Therapeutics, Inc. (NASDAQ: NTLA) presents a compelling case. Recent data highlights a significant potential upside of 149.52%, positioning Intellia..

SIGA Technologies Inc. (SIGA) Stock Analysis: Evaluating the Growth Potential in the Health Security Arena

SIGA Technologies Inc. (NASDAQ: SIGA) stands as a pivotal player in the healthcare sector, specifically within the niche of drug manufacturing for specialty and generic products. With a market capitalization..

CorMedix Inc. (CRMD) Stock Analysis: Exploring a Potential 63% Upside

Investors with a keen eye on the biotechnology sector should take a closer look at CorMedix Inc. (NASDAQ: CRMD), a promising biopharmaceutical company that has captured significant attention with its..

Sionna Therapeutics, Inc. (SION) Investor Outlook: Potential Upside and Analyst Confidence in Biotech Innovator

Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning player in the biotech sector, has captured the attention of investors with its promising portfolio targeting cystic fibrosis (CF). Headquartered in Waltham, Massachusetts,..

Owens & Minor, Inc. (OMI)

⚠️ No article content returned.

..

Xencor, Inc. (XNCR) Stock Analysis: Exploring an 84% Potential Upside in the Biotech Sector

Investors with a keen interest in the biotechnology sector would do well to keep an eye on Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company based in Pasadena, California. With..

LifeMD, Inc. (LFMD) Stock Analysis: Unveiling a Potential 171% Upside in Telehealth

LifeMD, Inc. (NASDAQ: LFMD), a prominent player in the burgeoning telehealth industry, is currently trading at a price of $3.41, with a market capitalization of approximately $164.14 million. Despite a..

KalVista Pharmaceuticals (KALV) Stock Analysis: A Biotech Contender with a 91.95% Upside Potential

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a prominent player in the biotechnology sector, has been making waves with its promising therapeutic candidates. Based in Cambridge, Massachusetts, this biopharmaceutical company focuses on..

Day One Biopharmaceuticals (DAWN) Stock Analysis: Uncovering a 138% Potential Upside in the Biotechnology Sector

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) has emerged as a noteworthy player in the biotechnology industry, capturing investor attention with a compelling potential upside of 138.73%. This commercial-stage company is..

Enhabit, Inc. (EHAB) Stock Analysis: Navigating a 5.75% Potential Upside in the Healthcare Sector

Enhabit, Inc. (NASDAQ: EHAB) is a notable player in the healthcare sector, specifically within the medical care facilities industry. Based in Dallas, Texas, Enhabit specializes in providing home health and..

Vir Biotechnology, Inc. (VIR) Investor Outlook: Exploring the 185.61% Potential Upside

Vir Biotechnology, Inc. (NASDAQ: VIR) stands out in the biotechnology sector, primarily due to its ambitious approach to combating serious infectious diseases through a robust pipeline of investigational therapies. With..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: 65.71% Upside Potential Draws Investor Attention

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, is catching the eyes of investors with its promising pipeline and substantial upside potential. As the company focuses on developing novel..

Immunome, Inc. (IMNM) Stock Analysis: Evaluating the 59% Potential Upside in Biotech Innovation

Immunome, Inc. (NASDAQ: IMNM), a trailblazer in the biotechnology sector, is capturing investor attention with its promising portfolio of targeted cancer therapies. As a clinical-stage company dedicated to the development..

Zevra Therapeutics, Inc. (ZVRA): Investor Outlook with a 151.6% Potential Upside

Investors seeking high-growth opportunities in the biotechnology sector should take a closer look at Zevra Therapeutics, Inc. (NASDAQ: ZVRA). With a focus on addressing unmet medical needs in rare diseases,..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 126.63% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stands as a beacon of innovation in the biotechnology sector, focusing on the development of gene therapies for rare and life-threatening diseases. With a market..

Talkspace, Inc. (TALK) Stock Analysis: Potential 33.81% Upside as Digital Healthcare Expands

Talkspace, Inc. (NASDAQ: TALK) is making waves in the rapidly growing digital healthcare sector. As a virtual behavioral healthcare company, Talkspace connects patients with licensed mental health providers via an..

Investor Outlook: Amylyx Pharmaceuticals (AMLX) Offers 67.4% Upside Potential Amid Strong Buy Ratings

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) stands as a compelling player in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. Based in Cambridge, Massachusetts, this clinical-stage pharmaceutical..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds